This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Health care professionals all agree that a healthy diet is the foundation of cardiovascular and cardiometabolic health, but follow-through on the population level is lacking.
In addition to a rapid deterioration, psychosis in Alzheimer disease can also lead to poorer quality of life, damaging patients’ relationships with caregivers, and increases isolation.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
First Opinion is STAT’s platform for interesting, illuminating, and maybe even provocative articles about the life sciences writ large, written by biotech insiders, health care workers, researchers, and others. To encourage robust, good-faith discussion about issues raised in First Opinion essays, STAT publishes selected Letters to the Editor received in response to them.
Vraylar is an atypical antipsychotic drug commonly prescribed for the treatment of schizophrenia and bipolar disorder, and it can also be used to treat other psychiatric disorders. It’s typically covered under commercial health insurance plans as well as Medicare and Medicaid. Medicare coverage of Vraylar falls under Medicare Part D prescription drug coverage, and understanding how much you’ll pay for Vraylar with Medicare can be a little confusing.
The ability to breathe easily is something people may take for granted, but not people with severe eosinophilic asthma —when a certain type of white blood cells called eosinophils cause inflammation in the airways, impeding lung function. Often prescribed alongside systemic corticosteroids, Fasenra (benralizumab) is an injectable biologic medication that targets and eliminates those white blood cells.
Will Sanofi’s plan to recruit the younger generation through its participation in the upcoming 2024 Olympic and Paralympic Games, being held in Paris, pay off?
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Latuda (lurasidone) is a brand-name prescription drug that’s approved by the Food and Drug Administration (FDA) to treat schizophrenia as well as bipolar depression associated with bipolar I disorder. It’s also sometimes prescribed off-label to treat major depressive disorder and other mental health conditions. The price of Latuda can vary based on several factors, including your location, pharmacy, and insurance coverage.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content